JPMorgan Chase & Co. reduced its position in Inogen, Inc. (NASDAQ:INGN - Free Report) by 30.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 627,030 shares of the medical technology company's stock after selling 269,076 shares during the quarter. JPMorgan Chase & Co. owned about 2.63% of Inogen worth $5,750,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC acquired a new position in Inogen in the 4th quarter valued at $43,000. American Century Companies Inc. increased its stake in Inogen by 10.2% in the 4th quarter. American Century Companies Inc. now owns 54,856 shares of the medical technology company's stock valued at $503,000 after buying an additional 5,089 shares during the period. Geode Capital Management LLC increased its stake in Inogen by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company's stock valued at $5,377,000 after buying an additional 5,921 shares during the period. Intech Investment Management LLC acquired a new position in Inogen in the 4th quarter valued at $94,000. Finally, Ieq Capital LLC acquired a new position in Inogen in the 4th quarter valued at $94,000. 89.94% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research note on Wednesday, April 9th. StockNews.com downgraded shares of Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th.
Check Out Our Latest Analysis on INGN
Inogen Trading Up 7.0 %
Shares of INGN traded up $0.47 during trading hours on Wednesday, reaching $7.20. The company had a trading volume of 32,436 shares, compared to its average volume of 239,128. The company has a market capitalization of $193.59 million, a price-to-earnings ratio of -3.20 and a beta of 1.48. Inogen, Inc. has a 12-month low of $6.40 and a 12-month high of $13.33. The firm has a 50 day simple moving average of $7.80 and a 200-day simple moving average of $9.10.
Inogen Profile
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Recommended Stories
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
